SECTION // 04 — DOSE CONTEXT
BPC-157 TB-500 Dosage: What the Animal Studies Used, and What They Did Not Validate
There is no validated dose for the blend. The figures here are the doses administered to specific species in specific studies — research context, never a human protocol.
BPC-157 and TB-500 Dosage Ranges in Preclinical Studies
BPC-157 TB-500 dosage, in the published record, exists only at the level of the individual constituents and only in animal and biochemical studies. There is no validated dose for the blend, and the figures below are reported as "studied at X in [species]," never as a recommendation for human use [9].
BPC-157 component (animal models). Rodent studies commonly express dose per body weight. The transected-Achilles-tendon work used 10 microg/kg or 10 ng/kg [1]; gastric-ulcer cytoprotection has been studied in rats at roughly 400-800 ng/kg [9]. These are the dose magnitudes behind the BPC-157 channel's tendon and cytoprotection findings.
TB-500 / Thymosin Beta-4 component (animal models). The range is wide and the schedules differ by model. A rat embolic-stroke dose-response study spanned 2-18 mg/kg intraperitoneal, with an optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit — direct evidence that higher is not always better [4]. An mdx muscular-dystrophy study used 150 microg twice weekly for six months [4].
The blend itself. Commercial research-product labeling commonly pairs BPC-157 and TB-500 at fixed combined masses per vial — for example, roughly 10 mg plus 10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists, so no ratio or dose for the assembled blend has been validated [3][9].
Routes Studied in the Component Literature
Routes Studied in the Component Literature
The routes in the underlying research are several, and the "wolverine injection" framing common online maps onto routes studied in animals, not validated human-use instructions. The predominant routes in the rodent efficacy studies for both peptides are intraperitoneal; subcutaneous and intramuscular are the predominant research-community routes for the blend, though not from controlled human efficacy trials [9]. Intravenous appears in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 IV safety pilot, and local or intra-lesional and topical routes appear in individual-compound wound and tendon models [9].
Oral vs. Parenteral Administration in Preclinical Models
BPC-157 is studied as a "stable gastric" peptide, which is the basis for interest in oral administration, and the "bpc 157 tb 500 oral" question follows from that framing [9]. But marketed oral blend products lack validated pharmacokinetics: there is no established oral PK for the assembled BPC-157 plus TB-500 blend, and the parenteral routes above dominate the efficacy literature for both constituents [9]. Oral interest is a property of one component, not a validated delivery route for the pair.
Half-life, reconstitution, and frequency
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [9]. Human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [9].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [9]. Commercial vials are commonly labeled with a combined per-vial mass (for example, 10 mg plus 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [3]. No human-use reconstitution instructions apply to a research chemical.
How often should you inject BPC-157 and TB-500?
There is no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — for example, Thymosin Beta-4 at 150 microg twice weekly for six months in one mouse study [4] — and community frequency protocols have no controlled-trial basis. The defensible framing is "studied at X in [species]," not a recommended human schedule [9].
How do you cycle BPC-157 and TB-500?
No validated human cycling protocol exists. Community "loading then maintenance" blend protocols have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — undermining "more is better" loading rationales [4]. Component animal studies use widely differing schedules by species and route [9]. For the half-life and reconstitution notes, see the entries above on this page.